GO SAFE Study

Geriatric Oncology Surgical Assessment and Functional rEcovery after Surgery

An international prospective audit to evaluate postoperative functional outcomes and quality of life after cancer surgery in geriatric patients
## KEY TRIAL CONTACTS

<table>
<thead>
<tr>
<th>Role</th>
<th>Contact Person</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Investigator:</td>
<td>Prof. Giampaolo Ugolini</td>
<td>Alma Mater University of Bologna Ospedale degli Infermi, Faenza (RA), IT General Surgery Unit Telephone +39 349 4347576 e-mail address: <a href="mailto:g.ugolini@unibo.it">g.ugolini@unibo.it</a></td>
</tr>
<tr>
<td>Co-Investigators:</td>
<td>Dr. Barbara Van Leeuwen</td>
<td>Dept. of Surgical Oncology UMCG, Groningen, NL</td>
</tr>
<tr>
<td>Sponsor/Promoter:</td>
<td>AUSL della Romagna</td>
<td>Via de Gasperi 8 48121 Ravenna</td>
</tr>
<tr>
<td>Study management:</td>
<td>Unità di Biostatistica e Sperimentazioni Cliniche</td>
<td>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l IRCCS Via Piero Maroncelli, 40/42 47014 Meldola (FC) Telephone + 390544285813 Fax +390544285330 e-mail address: <a href="mailto:cc.ubsc@irst.emr.it">cc.ubsc@irst.emr.it</a></td>
</tr>
<tr>
<td>Statistician:</td>
<td>Dr. Oriana Nanni</td>
<td>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l IRCCS Via Piero Maroncelli, 40/42 47014 Meldola (FC) e-mail address: <a href="mailto:oriana.nanni@irst.emr.it">oriana.nanni@irst.emr.it</a></td>
</tr>
</tbody>
</table>
**Steering committee:**

**Riccardo Audisio**  
Dept. of Surgical Oncology - St Helens Hospital Liverpool, UK

**Nicola De Liguori Carino**  
HBP Surgery, Manchester Royal Infirmary, UK

**Giorgio Ercolani**  
Alma Mater University of Bologna - General Surgery Unit - Ospedale Morgagni, Forlì, IT

**Nadav Haim**  
Colorectal surgery Sheba Medical Center Ramat Gan, HaMerkaz, Israel

**Michael Jaklitsch**  
Dept of Thoracic Surgery - Brigham and Women's Hospital, Boston, MA, USA

**Isacco Montroni**  
General Surgery Unit - Ospedale degli Infermi, Faenza, IT

**Siri Rostoft**  
Dept. of Geriatric Oncology, Oslo University Hospital, NW

**Ponnandai Somasundar**  
Dept. of Surgical Oncology, Roger Williams Medical Center Providence - Boston University, RI, USA

**Promoted by SIOG surgical task force and ESSO**

**Confidentiality Statement**  
This document contains confidential information that must not be disclosed to anyone other than the Sponsor/Promoter, the Investigator’s Team, IRST IRCCS, regulatory authorities, and members of the Ethics Committee.
Protocol approval and Investigator agreement

Geriatric Oncology Surgical Assessment and Functional rEcovery after Surgery

The undersigned agree and confirm that:

The following protocol has been agreed and accepted and the Chief Investigator agrees to conduct the trial in compliance with the approved protocol and will adhere to the principles outlined in ICH GCP guidelines, Sponsor/Promoter SOP’s and other regulatory requirements as amended.

The confidential information contained in this document will not be used for any other purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of the Sponsor/Promoter.

The findings of the study will be made publically available through publication or other dissemination tools without any unnecessary delay and that an honest accurate and transparent account of the study will be given; and any discrepancies from the study as planned in this protocol will be explained.

Giampaolo Ugolini
Chief Investigator
Signature Date

Oriana Nanni
Trial Statistician
Signature Date

By signing this document I am confirming that I have read the protocol for the above study and I agree to conduct the study in compliance with the protocol and ICH GCP.

_________________
Principal Investigator Signature Date
ABBREVIATIONS

AE  Adverse event
AR  Adverse reaction
CC  Coordinating Center
CI  Chief Investigator
CRA  Clinical Research Associate (Monitor)
CRF  Case Report Form
CRO  Contract Research Organisation
CT  Clinical Trials
CTC  Common toxicity criteria
ECOG  Performance status (Eastern Cooperative Oncology Group, ECOG Scale)
FR  Functional recovery
GCP  Good Clinical Practice
IB  Investigators Brochure
ICF  Informed Consent Form
ICH  International Conference of Harmonisation
IDMC  Indipendent Data Monitoring Committee
IEC  Independent Ethics Committee
IMP  Investigational Medicinal Products
IRB  Independent Review Board
PI  Principal Investigator
QoL  Quality of Life
RECIST  Response Evaluation Criteria In Solid Tumors
SAE  Serious Adverse Event
SAR  Serious Adverse Reaction
SOP  Standard Operating Procedure
SUSAR  Suspected Unexpected Serious Adverse Reactions
WHO  World Health Organization
TABLE OF CONTENTS

KEY TRIAL CONTACTS.................................................................................................................................................. 2

STEERING COMMITTEE: .................................................................................................................................................. 3

1. BACKGROUND .......................................................................................................................................................... 8

2. RATIONALE .............................................................................................................................................................. 9

3. AIM OF THE STUDY .................................................................................................................................................... 9

   3.1 PRIMARY OBJECTIVE ........................................................................................................................................ 10

   3.2 SECONDARY OBJECTIVES ................................................................................................................................ 10

4. STUDY PROTOCOL .................................................................................................................................................... 10

   4.1 CENTRES AND INVESTIGATORS ....................................................................................................................... 10

   4.2 STUDY DESIGN .................................................................................................................................................... 11

   4.3 STUDY POPULATION .......................................................................................................................................... 11

      4.3.1 INCLUSION CRITERIA .................................................................................................................................. 11

      4.3.2 EXCLUSION CRITERIA ................................................................................................................................ 11

   4.4 LOCAL APPROVALS ........................................................................................................................................... 12

5. PROCEDURES AND DATA COLLECTION ................................................................................................................... 12

   5.1 INFORMED CONSENT ......................................................................................................................................... 12

   5.2 REGISTRATION (CRF A) .................................................................................................................................. 12

   5.3 DATA COLLECTION ............................................................................................................................................. 13

      5.3.1 BASELINE EVALUATION (CRF B) ............................................................................................................ 13

      5.3.2 OPERATIVE DETAILS AND EARLY POSTOPERATIVE OUTCOME (CRF C) .............................................. 14

      5.3.3 FOLLOW UP (CRF 3M-6M) ....................................................................................................................... 15

   5.4 STUDY PLAN FLOWSHEET AND CRF COMPLETION TIMES ............................................................................. 16

   5.5 CONFIDENTIALITY .............................................................................................................................................. 16

   5.6 DATA QUALITY ASSURANCE ........................................................................................................................... 17

6 STATISTICAL CONSIDERATIONS ............................................................................................................................. 17

   6.1 DATA ANALYSIS .................................................................................................................................................. 17

   6.2 SAMPLE SIZE ..................................................................................................................................................... 17

   6.3 STUDY DURATION ............................................................................................................................................... 18

7 WITHDRAWAL OF PATIENTS FROM THE STUDY ...................................................................................................... 18
8 ETHICAL ASPECTS .............................................................................................................................................18
  8.1 LOCAL REGULATIONS/DECLARATION OF HELSINKI ................................................................. 18
  8.2 INDEPENDENT ETHICAL COMMITTEE ..................................................................................... 18
  8.3 INFORMED CONSENT .................................................................................................................. 19
  8.4 PATIENT DATA PROTECTION ........................................................................................................... 19

9 ADMINISTRATIVE REGULATIONS ..................................................................................................................19
  9.1 CURRICULUM VITAE ....................................................................................................................... 20
  9.2 SECRECY AGREEMENT ..................................................................................................................... 20
  9.3 FINANCIAL ARRANGEMENTS .......................................................................................................... 20

10 OWNERSHIP OF THE DATA AND USE OF THE STUDY RESULTS ......................................................20

11 PUBLICATION POLICY AND AUTHORSHIP .........................................................................................20

12 PROTOCOL AMENDMENTS .......................................................................................................................21

13 REFERENCES ..................................................................................................................................................22
1. BACKGROUND

Progressive aging of the world population has become one of the most significant challenges for national health care systems. With aging, the incidence and prevalence of cancer increases: it has been estimated that in 2020 more than 60% of all malignancies will occur in patients aged 70-year and older. At the same time, progress in medical knowledge has determined an extremely positive impact in clinical practice. In particular, improvements in perioperative care, surgical minimally invasive techniques and the introduction of multimodal treatment have made surgery feasible for a higher number of patients. Nevertheless, several studies show that senior adults affected by cancer are often treated sub-optimally, above all in the surgical field.

It is well known that onco-geriatric patients are at higher risk of developing postoperative complications because they are often affected by multiple comorbidities. It has been reported that up to 80% of elderly patients might experience a surgical complication. Thus, after major surgery, patients may be at risk of both developing postoperative complications, and suffering major discomfort that can negatively affect postoperative quality of life.

The vast majority of research studies are focused on short-term outcomes and do not explore long-term disability or postoperative quality of life.

Onco-geriatric patients represent a challenge for surgical oncologists because, despite the evidence that comorbidities are often responsible for poor postoperative outcomes, patients’ selection has not been completely standardized yet. Preoperative assessment of the functional status is fundamental to identify fit, vulnerable and frail individuals in order to avoid under- or over-treatment. Functional recovery has been shown to be of critical value in the elderly population since restoration/conservation of independence is probably the most important end-point for senior adults. Individualization of elderly cancer-patients care is closely related with the possibility of preserving their functional capacity. We could conclude that for elderly patients, perhaps more than anyone else, “quality” is more important than “quantity” of life.
2. RATIONALE

We aim to improve outcomes of onco-geriatric patients’ surgical management. Our research project will focus on quality of life and functional recovery after surgery. The most important expected result will be the collection of data that clinicians will be able to exploit in the management of frail and ‘pre-frail’ patients with the potential to reduce disparities in elderly patient care. In addition, the ‘multidisciplinary work ethic’ in the management of this specific group of patients, regardless for their primary condition, will be extensively promoted to determine small but clinically important incremental improvements in elderly care.

We need to conduct the GO SAFE study for several reasons:

- There is a dramatic lack of knowledge on elderly cancer surgical patients
- Although survival is commonly reported after surgery, quality of life (QoL) and functional recovery (FR), including nutritional status, are rarely measured
- To promote the practice of a multidisciplinary management of elderly cancer patients
- To understand how frailty, comorbidities and malnourishment are associated with early and long-term clinical outcomes after surgery in elderly cancer patients
- To obtain prospective data to assist clinicians in tailoring the care, avoiding under/over-treatment
- To identify new strategies to improve functional outcomes (as cardiorespiratory/nutritional prehabilitation)

To identify areas warranting further research studies and surgical audit in the older adults cancer population

3. AIM OF THE STUDY

GO SAFE study is a prospective international collaborative high-quality registry aiming to gain knowledge about postoperative outcomes in older cancer patients with a particular emphasis on QoL and FR. The target is to obtain meaningful data to assist clinicians in tailoring the care,
avoiding under/over-treatment, providing robust data to identify new strategies to improve functional outcomes in older cancer patients.

3.1 Primary Objective
To evaluate the effects of surgery on patients’ life perception by comparing pre- and post-operative QoL in elderly patients undergoing major surgery for solid malignancies using a self-reported Quality of Life assessment tool (EQ 5D-3L)

3.2 Secondary Objectives
- To evaluate FR in terms of nutritional status, restoration of daily activities (ADL) and cognitive status (Mini-Cog)
- To evaluate 3 and 6 months postoperative morbidity and mortality
- To obtain prognostic factors for postoperative functional recovery which will assist in the treatment planning /intervention of future elderly patients who are offered surgery for cancer
- To identify variables affecting postoperative quality of life

4. STUDY PROTOCOL

4.1 Centres and Investigators
We aim to involve in the study as many centers as possible. All surgical units performing cancer surgery in elderly patients are invited to participate. Participating investigators will be surgical oncologists. Each center will require approval from local Institutional Review Board and/or the Ethic Committee before starting to enroll patients.

Investigators will be responsible to obtain a written informed consent from each eligible patient in according to the local IRB regulation, ahead of surgery (please see note below in case of demented patients). Every center shall commit to send clinical data after the 6-month follow up.
Periodic evaluation of patient data entry, centers’ activity, and cohesion of the centers will be shared among the investigators.

4.2 Study Design
GO SAFE is a multicenter international observational prospective cohort study. The study is non-for-profit. Recruiting centers will collect data prospectively. Recruited patients will be followed for 6 months after their surgery. The original treatment plan, as designed by each individual recruiting centre, will not be altered or affected by the study inclusion.

4.3 Study Population
Centers should ensure that they would make every possible effort to include all consecutive eligible patients during the study period and provide completeness of data entry to ensure a ‘real-life’ study.

4.3.1 Inclusion Criteria
1. All consecutive patients, both gender, aged ≥70
2. Patients affected by solid malignancy
3. Patients undergoing elective major surgical procedures with curative or palliative intent (all major procedures including any resection, for any cancer, via any operative approach, open, laparoscopic, robotic, etc…)
4. Informed consent obtainment

4.3.2 Exclusion criteria
1. Patients undergoing emergent/urgent surgical procedures
2. Planned hospital stay less than 48 hours
4.4 Local approvals

Inclusion in the study does not imply any deviation from the current standard of practice, and no change is expected to the perioperative treatment at any point. Patients will be only asked to complete simple screening/assessment tests: for this reason this study should be registered as a prospective observational study at each participating hospital IRB. It is the responsibility of the local team to ensure that regulatory process is completed for its hospital. Participating centres will be asked to confirm that they have gained formal approval and to provide an Identification Number.

5. PROCEDURES AND DATA COLLECTION

5.1 Informed Consent

It is the responsibility of the investigator, or a person designated by the investigator, to obtain (if applicable) written informed consent from each individual participating in this study. When applicable, each patient must personally sign and date the latest approved version of the Informed Consent form before any study specific procedures are performed. Patients must receive an explanation that they are completely free to refuse to enter in this study and to withdraw from it at any time and for any reason without prejudice to future care, and with no obligation to give the reason for withdrawal. The original signed form will be retained at the study site. A copy of the informed consent form will be delivered to the patient. A form for obtaining written informed consent for this observational study will be provided.

5.2 Registration (CRF A)

All patients for whom eligibility criteria have been verified will be registered by each participating center in the eCRF. The following data will be collected at registration:

- Patient’s Date of birth
- Patient’s Gender
- Date of Informed consent
- Date of registration
5.3 Data Collection

Clinical reporting forms (CRFs) have been designed to be completed along the normal daily-life practice, trying to minimize the ‘extra work’ for local investigators. Tests, carried out at baseline and follow-up evaluation, could be easily completed by surgical trainees, medical students and nurses adequately trained. Surgical data analysis, including detection of postoperative complications, should require the supervision of an attending/consultant surgeon.

CRFs are to be completed through use of an EDC system. Sites will have access to a manual for appropriate CRF completion. All CRFs should be completed by designated, trained site staff. CRFs should be reviewed and electronically signed and dated by the investigator or a designee. If a correction is required for an CRF, the EDC system will create an electronic audit trail.

Participants must maintain quality of their database and update their database. Access to the raw data will be according to agreement of both parties. Each center must keep a file of all consecutive patients that have been entered in the database for random quality monitoring.

5.3.1 Baseline evaluation (CRF B)

For every eligible patient, demographic data will be collected followed by a fast preoperative functional assessment including:

- Charlson Comorbidity Index
- “Timed Up and Go” test
- Nutritional Risk Screening (NRS)
- American Society of Anesthesiology (ASA) score
- ECOG Performance Status
- G8 geriatric screening tool
- Mini-Cog
- Activities of Daily Living (ADL)
- Self-reported Quality of Life (EQ 5D-3L). This test will not be administered to patients with moderate-severe cognitive impairment (Mini-Cog< 3)
• History of delirium during illness or hospital admission
• History of Smoking
• History of falls in the 6 months prior to the operation
• Living situation
• Lab’s (Albumin, Hemoglobin, Creatinin)
• Polipharmacotherapy (total number of medications)
• Preoperative chemotherapy/radiation therapy
• Involvement of geriatric specialist in preoperative care

5.3.2 Operative details and early postoperative outcome (CRF C)
Data regarding surgical procedures and perioperative measures will be collected. Complications will be reported and graded according to Clavien-Dindo Classification.

• Cancer site
• Surgical Procedure Category: Ortho, Gyn, Breast, Upper-GI, Colorectal, HBP, Peritoneum, Thoracic (esophagus), Head & Neck, Urology
• Type of procedure (describe)
• Type of anesthesia (General, Spinal, Epidural)
• Type of surgery (palliative, curative)
• Duration of anaesthesia (min)
• Surgical approach (Open/Laparoscopic/Robotic….)
• Need of ICU stay (Y/N; n. days)
• Perioperative blood transfusions (Units of Packed RBC’s) within the surgical admission
• Postoperative length of stay (days in surgical unit)
• Patient discharged to same preoperative setting
• Patient transferred to Medicine/Rehabilitation facility
• Tumor stage (TNM/Stage)
• Involvement of geriatric specialist in postoperative care
• 30 day morbidity (Clavien-Dindo)
• 30 day mortality

5.3.3 Follow up (CRF 3M-6M)
Three- and six-month follow up data will be collected after surgery within a range of 2 weeks from the due date.

<table>
<thead>
<tr>
<th>Data</th>
<th>3 months</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morbidity (Clavien-Dindo)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Mortality</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Living situation</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Weight</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Nutritional Screening</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>“Timed Up and Go” test</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Mini-Cog</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ECOG Performance Status</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ADL</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Self-reported Quality of Life (EQ 5D-3L)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Postoperative Chemotherapy</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Postoperative Radiation Therapy</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Rehabilitation program</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Nutritional supplement</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
• Involvement of a geriatric specialist

Local investigators should be also proactive in identifying postoperative events. For example they may review patients notes during admission and before discharge, as well as they could review hospital and outpatient clinic systems to check for readmission and/or other unplanned events.

### 5.4 Study plan flowsheet and CRF completion times

<table>
<thead>
<tr>
<th>REGISTRATION</th>
<th>CRF A</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREOPERATIVE ASSESSMENT</td>
<td>CRF B</td>
</tr>
<tr>
<td>(BASELINE EVALUATION)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OPERATIVE DETAILS</th>
</tr>
</thead>
<tbody>
<tr>
<td>EARLY POSTOPERATIVE OUTCOME (1 month)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FOLLOW UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months</td>
</tr>
<tr>
<td>6 months</td>
</tr>
</tbody>
</table>

### 5.5 Confidentiality

Personal patients’ data will not be shared to anyone outside of the research team. The information collected in this research project will be kept private. All patient information will be anonymized. The database used is certified, highly secured and is stored in a encrypted server that meets all the requirements for data-safety and privacy set by international law.
5.6 Data quality assurance

- Medical review with investigators
- CRF quality check, query firing, data cleaning
- Early feedback with local research team via teleconferences

6 STATISTICAL CONSIDERATIONS

6.1 Data analysis
The Full Analysis Set (FAS) consists of all registered patients.

The primary endpoint will be measured for all registered subjects who fulfill preoperative and postoperative EQ VAS. Demographic and baseline patient characteristics will be summarized for all patients in the FAS. Continuous-scaled variables (e.g., age) will be summarized with means, medians, standard deviations, quartiles, and minimum and maximum values. Categorical variables (e.g., sex) will be summarized using patient counts and percentages. Study endpoints and variables will be evaluated using descriptive statistics, and the key figures of the distributions will be presented in tables. Univariate analyses will allow for a first overview of potentially influential factors.

Multiple linear regression models will be performed in order to evaluate predictors of functional recovery at 3 months and 6 months after surgery.

Exploratory subgroup analyses will be performed. Missing values will be replaced and estimated using multiple imputations. Furthermore, sensitivity analysis will be executed using complete-case analysis.

6.2 Sample size
A sample size of 265 patients who completed pre and postoperative EQ VAS questionnaires will have a 90% power to detect an effect size of 0.2 between pre and post surgery, using a paired t-test with a 0.05 two sided significance level.

Given a potential loss to follow-up (about 10%), uncompleted questionnaires (about 10%) and postoperative mortality (about 15%), the sample size will be increased to 350-400 patients (see
6.3 **Study duration**

Enrollment period: 24 months  
Follow-up: 6 months  
Data analysis: 6 months  
Total duration of the study: 36 months

7 **WITHDRAWAL OF PATIENTS FROM THE STUDY**

Patients have the right to withdraw at any time for any reason during their participation in this observational study.

8 **ETHICAL ASPECTS**

8.1 **Local regulations/Declaration of Helsinki**

The responsible Investigator will ensure that this study is conducted in compliance with the protocol, following the instructions and procedures described, adhering to the principles of Good Clinical Practice ICH Tripartite Guideline (December 2000) and in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964 and further amendments) or with the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual.

8.2 **Independent Ethical Committee**

The protocol, informed consent and any accompanying material provided to the patient will be submitted by the investigator to an Independent Ethical Committee for review. Approval from the committee must be obtained before starting the study. Any modifications made to the protocol, informed consent or material provided to the patient after receipt of the Ethics Committee approval must also be submitted by the investigator to the Committee in accordance with local procedures and regulatory requirements. The Independent Ethical
Committee approval report must contain details of the trial (title, protocol number and version), documents evaluated (protocol, informed consent, accompanying material) and the date of the approval.

8.3 Informed Consent
It is the responsibility of the Investigator to obtain written informed consent from each subject prior to entering the trial or, where relevant, prior to evaluating the subject's suitability for the study.

The informed consent document used by the Investigator for obtaining the subject’s informed consent must be reviewed and approved by the Ethical Committee.

A copy of the patient's signed written consent will be kept by the center in the proper section of the Investigator Site File.

8.4 Patient data protection
The Informed Consent Form will incorporate wording that complies with relevant data protection and privacy legislation. In agreement with this wording, patients will authorize the collection, use and disclosure of their study data and samples by the Investigator and by those persons who need that information for the purposes of the study.

The Informed Consent Form will explain that the study data will be stored in a computer database, maintaining confidentiality in accordance with national data legislation.

The Informed Consent Form will explain that the samples obtained by patients will be anonymized and stored in accordance with national data legislation.

The Informed Consent Form will also explain that for data verification purposes, authorized representatives of Sponsor/Promoter, a regulatory authority, an Ethics Committee may require direct access to parts of the hospital or practice records relevant to the study, including patients’ medical history.

9 ADMINISTRATIVE REGULATIONS
The Coordinating Center (CC) is responsible for drawing up the final version of the protocol, implementing the CRFs and the electronic database, defining general
organizational procedures and organizing periodic meetings and newsletters. The CC will also undertake the following: support for the preparation of all documents needed for EC submission of the study protocol for each participating center, training of staff assigned to data collection, definition of monitoring procedures.

9.1 Curriculum vitae
An updated copy of the curriculum vitae of each Principal Investigator, duly signed and dated, will be provided to the CC prior to the beginning of the study.

9.2 Secrecy agreement
All goods, materials, information (oral or written) and unpublished documentation provided to the Investigators, including this protocol and the case report forms, shall be considered confidential and may not be given or disclosed to third parties.

9.3 Financial Arrangements
This is a non-for-profit study promoted by SIOG surgical task force and ESSO. No registration fee is requested to participate to the GO SAFE study. No financial reimbursements will be made to participating centers/investigators.

10 Ownership of the Data and Use of the Study Results
Participants shall retain the ownership of their own data. Each participating center is responsible for accurate data entry and has access to their data only. No data sharing will be performed with any third party. Personal data will be anonymized and confidential encrypted in a secure place. Professional support for data analysis will be made available.

11 Publication Policy and Authorship
Clinical results will be published collaboratively. Interim and final analysis will be presented at scientific conferences to ensure visibility. Data will be published, acknowledging authorship to all the centers giving a substantial contribution, under the name of "SIOG (International Society of Geriatric Oncology)
surgical task force/ESSO (European Society of Surgical Oncology) GO SAFE study group”.

A maximum of 5 investigators from each individual surgical unit will be included as formal co-investigators in this research, and will be PubMed searchable and citable. The output from this research will be published on behalf of the ”SIOG (International Society of Geriatric Oncology) surgical task force/ESSO (European Society of Surgical Oncology) GO SAFE study group”.

Each hospital may participate with different surgical units (GI, HBP, etc…) and each unit should enrol a minimum number of 20 patients in order to claim authorship.

12 PROTOCOL AMENDMENTS

It is specified that the appendices, attached to this protocol and referred to in the main text of this protocol, form an integral part of the protocol.

No changes or amendments to this protocol may be made by the Investigators after the protocol has been agreed to and signed by both parties. Any change agreed upon will be recorded in writing, the written amendment will be signed by the Chief Investigator and by the Principal Investigator and the signed amendment will be appended to this protocol.

Approval / advice of amendments by Ethical Committees or similar body is required prior to their implementation, unless there are overriding safety reasons.

If the change or deviation increases risk to the study population, or adversely affects the validity of the clinical investigation or the subject’s rights, full approval / advice must be obtained prior to implementation. For changes that do not involve increased risk or affect the validity of the investigation or the subject’s rights, approval / advice may be obtained by expedited review, where applicable.

In some instances, an amendment may require a change to a consent form. The Investigator must receive approval / advice of the revised consent form prior to implementation of the change.
13 REFERENCES


17. Bravo Iñiguez CE, Armstrong KW, Cooper Z, Weissman JS, Ducko CT, Wee JO, Martinez...
